NASDAQ:KZRKezar Life Sciences Stock Price, Forecast & News

Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KZR shares have increased by 12.0% and is now trading at $4.47. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kezar Life Sciences.

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Kezar Life Sciences.

Kezar Life Sciences Inc (NASDAQ:KZR) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.07. View Kezar Life Sciences' earnings history.

4 equities research analysts have issued 12 month price targets for Kezar Life Sciences' shares. Their forecasts range from $12.00 to $18.00. On average, they expect Kezar Life Sciences' share price to reach $15.00 in the next year. This suggests a possible upside of 235.6% from the stock's current price. View analysts' price targets for Kezar Life Sciences.

News articles about KZR stock have been trending negative on Thursday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kezar Life Sciences earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutKezar Life Sciences.

Some companies that are related to Kezar Life Sciences include Cara Therapeutics (CARA), Kadmon (KDMN), Molecular Templates (MTEM), Retrophin (RTRX), Homology Medicines (FIXX), Eagle Pharmaceuticals (EGRX), Provention Bio (PRVB), Nabriva Therapeutics (NBRV), G1 Therapeutics (GTHX), Collegium Pharmaceutical (COLL), ZIOPHARM Oncology (ZIOP), Dynavax Technologies (DVAX), Ardelyx (ARDX), Trillium Therapeutics (TRIL) and Sinovac Biotech (SVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Opko Health (OPK), Gilead Sciences (GILD), ADMA Biologics (ADMA), Agile Therapeutics (AGRX), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Aptinyx (APTX), Clovis Oncology (CLVS) and Crispr Therapeutics (CRSP).

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (5.31%), BlackRock Inc. (5.10%), Victory Capital Management Inc. (3.59%), Victory Capital Management Inc. (3.59%), State Street Corp (1.12%) and Geode Capital Management LLC (1.11%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides. View institutional ownership trends for Kezar Life Sciences.

KZR stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, JPMorgan Chase & Co., RBF Capital LLC, Wells Fargo & Company MN, Deutsche Bank AG, and Alambic Investment Management L.P.. View insider buying and selling activity for Kezar Life Sciences.

KZR stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Victory Capital Management Inc., Victory Capital Management Inc., Geode Capital Management LLC, Alyeska Investment Group L.P., State Street Corp, and Nuveen Asset Management LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment, and Vassiliki Economides. View insider buying and selling activity for Kezar Life Sciences.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $4.47.

Kezar Life Sciences has a market capitalization of $170.66 million. The company earns $-35,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]